Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies

For older unfit patients receiving venetoclax-based induction, data on the significance of interim bone marrow biopies (BMBx) findings on clinical outcomes is lacking. We retrospectively evaluated interim BMBx results performed on Cycle 1 days 21-28 of venetoclax-based therapy in 69 adults with myeloid malignancies to determine whether blast clearance was associated with overall survival (OS) and overall response rate (ORR). Median age was 75 years (range 69-78). Results demonstrated blast reduction (BR, <5% blasts) in 71%. Venetoclax was held to allow count recovery in 86% of these patients. Achieving interim BMBx BR was significantly associated with OS (<i>p</i> = 0.0033) and ORR (Cohen's kappa 0.39). Patients whose venetoclax was held experienced low rates of infection and reduced cytopenias. These findings support the importance of cycle 1 BMBx assessment during venetoclax-based therapies, specifically in predicting which patients will achieve optimal outcomes and in mitigating toxicity.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2024-12-27
DOI
https://doi.org/10.1080/10428194.2024.2444480
Citations
1
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies

Jared Vega, Tara Cronin, Han Yu, Pamela J. Sung et al.
1 citations
Leukemia & lymphoma/Leukemia and lymphoma
Acute Myeloid Leukemia Research
0.45
article

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies

Jared Vega, Tara Cronin, Han Yu, Pamela J. Sung, Steven Green, Eunice S. Wang, Mark G. Faber, James E. Thompson, Elizabeth A. Griffiths, Daniel Appiah, Samantha Poblete, Amanda Przespolewski, Jeffrey Baron
article en
1 citations

Abstract

For older unfit patients receiving venetoclax-based induction, data on the significance of interim bone marrow biopies (BMBx) findings on clinical outcomes is lacking. We retrospectively evaluated interim BMBx results performed on Cycle 1 days 21-28 of venetoclax-based therapy in 69 adults with myeloid malignancies to determine whether blast clearance was associated with overall survival (OS) and overall response rate (ORR). Median age was 75 years (range 69-78). Results demonstrated blast reduction (BR, <5% blasts) in 71%. Venetoclax was held to allow count recovery in 86% of these patients. Achieving interim BMBx BR was significantly associated with OS (<i>p</i> = 0.0033) and ORR (Cohen's kappa 0.39). Patients whose venetoclax was held experienced low rates of infection and reduced cytopenias. These findings support the importance of cycle 1 BMBx assessment during venetoclax-based therapies, specifically in predicting which patients will achieve optimal outcomes and in mitigating toxicity.

Leukemia & lymphoma/Leukemia and lymphomaVol. 66(5)
Roswell Park Comprehensive Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Bristol-Myers Squibb (Germany) (DE), Bristol-Myers Squibb (United States) (US), The Bristol-Myers Squibb Children's Hospital (US), Banner MD Anderson Cancer Center
Zero hunger
Openalex Percentile: Top 28%
Acute Myeloid Leukemia Research
0.45
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.